CASI Stock Overview
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally.
CASI Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.97|
|52 Week High||US$10.30|
|52 Week Low||US$1.81|
|1 Month Change||-2.48%|
|3 Month Change||-47.75%|
|1 Year Change||-77.46%|
|3 Year Change||-93.82%|
|5 Year Change||-93.99%|
|Change since IPO||-99.89%|
Recent News & Updates
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?May 26
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ForecastsAug 14
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?May 25
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?Mar 16
Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In GrowthFeb 18
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?Jan 23
Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?Dec 28
Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%Dec 02
The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More SharesNov 27
|CASI||US Biotechs||US Market|
Return vs Industry: CASI underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: CASI underperformed the US Market which returned -14.8% over the past year.
|CASI Average Weekly Movement||10.5%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CASI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CASI's weekly volatility (11%) has been stable over the past year.
About the Company
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome.
CASI Pharmaceuticals, Inc. Fundamentals Summary
|CASI fundamental statistics|
Is CASI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CASI income statement (TTM)|
|Cost of Revenue||US$15.36m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.99|
|Net Profit Margin||-73.17%|
How did CASI perform over the long term?See historical performance and comparison